Heart Failure

Physical activity concentrated within a 1- to 2-day span was associated with a similarly lower risk of cardiovascular outcomes to more evenly distributed activity.

Anuradha Lala-Trindade, MD, provides an overview of SGLT2 inhibitors for the management of heart failure, as well as their clinical trial data.

An expert cardiologist reviews the foundational pillars of quadruple-based, guideline therapies for heart failure, as well as the contraindications for these drugs.

An analysis of NHANES data is offering clinicians an overview of associations between hyperuricemia and gout with increased risk of mortality in patients with heart failure.

Robert J. Mentz, MD, reviews the current unmet needs for patients with heart failure, highlighting triple or quadruple therapy.

Javed Butler, MD, MPH, MBA, comments on implementing, continuing or cutting back on quadruple therapy after patient’s cardiac function has improved.

Anuradha Lala-Trindade, MD, comments on the prevalence of the various types of heart failure, as well as risk factors leading to the disorder.

Anuradha Lala-Trindade, MD, discusses the challenges in managing heart failure in the United States as well as the universal definition of heart failure and classification by left ventricle ejection fraction (EF).

Drs James Januzzi, Javed Butler, Robert J. Mentz, and Muthiah Vaduganathan share approaches to sequencing quadruple therapy in heart failure to the individual patient, as well as optimizing therapy early in the hospitalization stage.

Javed Butler, MD, MPH, MBA, discussesSGLT-2 inhibitors and their use in heart failure.

Experts in cardiology highlight the four pillars of guideline directed therapies in heart failure.

Robert J. Mentz, MD, and James Januzzi, MD, discuss the key takeaways from updated heart failure guidelines, highlighting heart failure stages A and B.

A meta-analysis of 13 trials suggests SGLT2 inhibitors reduced heart failure events and cardiovascular death across these patient populations, with consistent effects in patients with varying disease combinations.

Muthiah Vaduganathan, MD, MPH, and Javed Butler, MD, MPH, MBA, share approaches to treating patients with heart failure, focusing on patient education as well as social determinants of health.

Experts in cardiology review the classification of heart failure using left ventricle ejection fraction (EF).

On June 15, 2023, Bristol Myers Squibb announced the FDA approved an updated label for mavacamten (Camzyos) to reflect the agent's ability to reduce the need or eligibility for septal reduction therapy in patients with obstructive HCM based on VALOR-HCM.

Muthiah Vaduganathan, MD, MPH, comments on the impact of recurrent rehospitalizations for heart failure on survival.

Javed Butler, MD, MPH, MBA, and Robert J. Mentz, MD, review the current prevalence of heart failure in the US and Europe, as well as the clinical and economic challenges that arise with increasing prevalence.

At the 7th Annual Heart in Diabetes meeting, Joseph discussed the need to advance equity in diabetes management, from clinical practice to community-based interventions.

Stephen Greene, MD, discusses the results of a recent GWTG-HF registry analysis, which concluded just 1 in 5 hospitalized patients with HFrEF were discharged with an SGLT2 inhibitor prescription and less than 10% were receiving all 4 classes of guideline-directed medical therapy.

Steve Greene, MD, discusses the results of a TRANSFORM-HF analysis comparing the effects of furosemide and torsemide on quality of life outcomes in patients with heart failure.

An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.

An analysis of Medicaid data from adults in Alabama suggests just more than 50% of patients fail to get ambulatory follow-up care within the recommended 14-day window following a first-time heart failure hospitalization.

Improved symptoms in 3 men with heart failure caused by ATTR-CM were confirmed by cardiovascular magnetic resonance scans showing the build-up of amyloid proteins had cleared.

12-month adherence to GLP1-RA or SGLT2i therapies was highest among individuals with T2D and/or heart failure with a low prescription co-payment.

Announced in a release by Daiichi Sankyo, Inc. and American Regent, Inc., the therapy is now the first and only intravenous iron replacement therapy indicated for adult patients with heart failure who have iron deficiency.

Scott Solomon, MD, of Brigham and Women's Hospital, discusses how baseline patient characteristics inform what cardiologists might learn from the FINEARTS-HF trial, which he presented at Heart Failure 2023.

Ahead of the sotagliflozin approval, Deepak Bhatt, MD, MPH, offers perspective into potential future research opportunities for the SGLT1/2 inhibitor and discusses the impact of a 3rd agent boasting SGLT2 inhibition receiving approval for heart failure.

The FDA approval of sotagliflozin (Inpefa) for the treatment of heart failure was announced by Lexicon Pharmaceuticals on May 26, 2023.

A posthoc analysis of the EMPEROR-Preserved trial suggested empagliflozin decreased the risk of heart failure hospitalization or cardiovascular death, regardless of background diuretic status.